The Indian government has confirmed that Rs 5,210 crore (approximately $625 million) has been invested under the Production Linked Incentive (PLI) scheme for Key Starting Materials (KSM), drug intermediates, and active pharmaceutical ingredients (APIs) — collectively referred to as “bulk drugs” — as of June 2026.
What the PLI Scheme Covers
The PLI scheme for pharmaceutical intermediaries and APIs was designed to reduce India’s dependence on imported bulk drugs — particularly from China — and strengthen domestic manufacturing of the building blocks that go into generic medicines. The scheme offers financial incentives based on incremental sales from products manufactured in India.
Rs 5,210 Crore: What This Means in Context
According to a government statement reported by PSU Watch on September 25, 2026, the cumulative investment of Rs 5,210 crore under the bulk drug PLI scheme reflects capital deployed by participating pharmaceutical companies to expand or establish manufacturing facilities for KSMs, intermediates, and APIs within India.
This figure covers investment commitments made by companies that were selected under the scheme’s approval rounds. The PLI framework offers tiered incentives — typically ranging from 5% to 10% of incremental sales — over a defined eligibility period, making the total committed investment a leading indicator of the scheme’s scale and industry participation.
Why Bulk Drug Self-Reliance Matters
India is the world’s largest exporter of generic medicines by volume, supplying affordable drugs to over 200 countries. However, a significant share of the raw materials — KSMs and APIs — used in these formulations has historically been sourced from China. The PLI scheme aims to shift this balance by making domestic bulk drug production commercially attractive.
For buyers of Indian generic medicines, stronger domestic bulk drug manufacturing has several practical implications:
- Supply chain resilience — reduced reliance on a single foreign source for critical raw materials
- Price stability — domestic production can buffer against import-driven cost shocks
- Regulatory alignment — locally manufactured KSMs and APIs can simplify CDSCO compliance and quality traceability
- Broader product range — more API categories produced domestically means a wider selection of finished generic formulations
The Broader Pharma Manufacturing Picture
The bulk drug PLI investment of Rs 5,210 crore is part of a larger push under India’s PLI framework, which also covers medical devices, pharmaceutical formulations, and critical technical textiles. Together, these schemes represent one of the most significant coordinated manufacturing incentives in the Indian pharmaceutical sector’s history.
The bulk drug focus is particularly notable because it targets the upstream side of the pharmaceutical value chain — the chemical and biological inputs that determine what medicines can be manufactured, at what cost, and with what quality controls. Without a robust domestic bulk drug base, even the most efficient formulation plants remain vulnerable to external supply disruptions, as seen during the pandemic period.
What Buyers and Importers Should Watch
For international buyers sourcing generic medicines from India, the PLI-driven expansion of domestic bulk drug manufacturing may gradually improve several procurement factors:
- More consistent API availability — broader domestic production reduces waiting times and supplier bottlenecks
- Improved quality documentation — locally produced KSMs and APIs under the PLI scheme are subject to Indian regulatory oversight, potentially simplifying vendor qualification
- Pricing dynamics — increased domestic capacity could stabilize or reduce input costs over the medium term, though scheme incentives and global demand will influence the pace
Buyers should continue to verify each supplier’s credentials, manufacturing licenses, and quality certifications independently. The PLI scheme is a manufacturing incentive program — it does not replace standard due diligence on individual manufacturers or distributors.
Source
Government of India, Ministry of Chemicals and Fertilizers, Pharmaceutical Division. Investment data reported via PSU Watch, September 25, 2026, citing official government figures as of June 2026.
For more information, contact IMSDA at contact@indiamedicine.org.